Results of a Phase III Trial that Explored Bevacizumab in Recurrent Cervical Cancer
Krishnansu S. Tewari, MD, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.
Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California Irvine in Orange, California, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.
Clinical Pearls
Patients with recurrent cervical cancer have few therapeutic options, Tewari notes. To help alleviate this, this trial compared a regimen of chemotherapy alone to chemotherapy plus bevacizumab and found an increase in overall survival of 3.7 months. Additionally, the side effect profile for the combination was consistent with expectations for bevacizumab as a monotherapy.
- Patients with recurrent cervical cancer have few therapeutic options
- A phase III trial performed by the GOG compared chemotherapy alone to chemotherapy plus bevacizumab
- The median OS for patients who received the combination was 17.0 months compared 13.3 months
- The side effect profile was consistent with bevacizumab monotherapy
<<<
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
